Bulletin
Investor Alert

Gilead Sciences Inc.

NAS: GILD

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Gilead Sciences Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 30, 2023, 6:35 p.m.

GILD
/zigman2/quotes/210293917/composite

$

81.10

Change

-0.35 -0.43%

Volume

Volume 358,445

Quotes are delayed by 20 min

/zigman2/quotes/210293917/composite

Today's close

$ 81.29

$ 81.45

Change

+0.16 +0.20%

Day low

Day high

$81.06

$81.90

Open

52 week low

52 week high

$57.17

$89.74

Open

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology,...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Valuation

P/E Current

22.34

P/E Ratio (with extraordinary items)

22.38

P/E Ratio (without extraordinary items)

23.59

Price to Sales Ratio

4.00

Price to Book Ratio

5.04

Price to Cash Flow Ratio

11.94

Enterprise Value to EBITDA

9.31

Enterprise Value to Sales

4.42

Total Debt to Enterprise Value

0.20

Efficiency

Revenue/Employee

1,593,235.00

Income Per Employee

270,118.00

Receivables Turnover

5.84

Total Asset Turnover

0.41

Liquidity

Current Ratio

1.29

Quick Ratio

1.15

Cash Ratio

0.61

Profitability

Gross Margin

79.11

Operating Margin

39.72

Pretax Margin

21.47

Net Margin

16.95

Return on Assets

7.00

Return on Equity

21.71

Return on Total Capital

22.70

Return on Invested Capital

10.10

Capital Structure

Total Debt to Total Equity

118.79

Total Debt to Total Capital

54.29

Total Debt to Total Assets

39.94

Long-Term Debt to Equity

108.08

Long-Term Debt to Total Capital

49.40

Officers and Executives

Name Age Officer Since Title
Mr. Daniel P. O'Day 56 2019 Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson 51 2016 Chief Financial Officer
Dr. Merdad V. Parsey - 2019 Chief Medical Officer
Dr. Flavius Martin - 2021 Executive Vice President-Research
Ms. Johanna Mercier 50 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/13/2023 Merdad V. Parsey
Chief Medical Officer 		6,126   Disposition at $78.99 per share. 483,892
03/10/2023 Daniel P. O'Day
Chairman & CEO; Director 		14,017   Derivative/Non-derivative trans. at $79.5 per share. 1,114,351
03/10/2023 Andrew D. Dickinson
Chief Financial Officer 		4,849   Derivative/Non-derivative trans. at $79.5 per share. 385,495
03/10/2023 Johanna Mercier
Chief Commercial Officer 		5,116   Derivative/Non-derivative trans. at $79.5 per share. 406,722
03/10/2023 Merdad V. Parsey
Chief Medical Officer 		5,328   Derivative/Non-derivative trans. at $79.5 per share. 423,576
03/10/2023 Sandra K. Patterson
SVP, Controllership 		801   Derivative/Non-derivative trans. at $79.5 per share. 63,679
03/10/2023 Daniel P. O'Day
Chairman & CEO; Director 		10,800   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Daniel P. O'Day
Chairman & CEO; Director 		19,488   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Andrew D. Dickinson
Chief Financial Officer 		7,394   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Andrew D. Dickinson
Chief Financial Officer 		3,025   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Johanna Mercier
Chief Commercial Officer 		7,951   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Johanna Mercier
Chief Commercial Officer 		3,025   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Merdad V. Parsey
Chief Medical Officer 		7,999   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Merdad V. Parsey
Chief Medical Officer 		3,455   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Sandra K. Patterson
SVP, Controllership 		1,320   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2023 Sandra K. Patterson
SVP, Controllership 		1,601   Derivative/Non-derivative trans. at $0 per share. 0
03/09/2023 Kevin E. Lofton
Director 		8,442   Derivative/Non-derivative trans. at $52.38 per share. 442,191
03/01/2023 Daniel P. O'Day
Chairman & CEO; Director 		4,842   Derivative/Non-derivative trans. at $79.59 per share. 385,374
03/01/2023 Merdad V. Parsey
Chief Medical Officer 		12,984   Disposition at $79.96 per share. 1,038,200
03/01/2023 Daniel P. O'Day
Chairman & CEO; Director 		11,362   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2023 Andrew D. Dickinson
Chief Financial Officer 		376   Award at $56.38 per share. 21,198
02/15/2023 Merdad V. Parsey
Chief Medical Officer 		376   Award at $56.38 per share. 21,198
02/15/2023 Deborah H. Telman
EVP, Corporate Affairs & GC 		376   Award at $56.38 per share. 21,198
02/06/2023 Andrew D. Dickinson
Chief Financial Officer 		531   Derivative/Non-derivative trans. at $86.36 per share. 45,857
02/06/2023 Diane E. Wilfong
SVP, Controller & CAO 		565   Derivative/Non-derivative trans. at $86.36 per share. 48,793
02/06/2023 Andrew D. Dickinson
Chief Financial Officer 		1,817   Derivative/Non-derivative trans. at $0 per share. 0
02/06/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,864   Derivative/Non-derivative trans. at $0 per share. 0
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		59,078   Derivative/Non-derivative trans. at $84.02 per share. 4,963,733
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		15,327   Derivative/Non-derivative trans. at $84.02 per share. 1,287,774
01/24/2023 Johanna Mercier
Chief Commercial Officer 		15,325   Derivative/Non-derivative trans. at $84.02 per share. 1,287,606
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		17,749   Derivative/Non-derivative trans. at $84.02 per share. 1,491,270
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,244   Derivative/Non-derivative trans. at $84.02 per share. 104,520
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		136,647   Award at $0 per share. 0
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		78,370   Award at $0 per share. 0
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		38,270   Award at $0 per share. 0
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		27,932   Award at $0 per share. 0
01/24/2023 Johanna Mercier
Chief Commercial Officer 		38,270   Award at $0 per share. 0
01/24/2023 Johanna Mercier
Chief Commercial Officer 		29,124   Award at $0 per share. 0
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		43,715   Award at $0 per share. 0
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		29,644   Award at $0 per share. 0
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		4,100   Award at $0 per share. 0
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,784   Award at $0 per share. 0
12/30/2022 Merdad V. Parsey
Chief Medical Officer 		553   Disposition at $85.33 per share. 47,187
12/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		1,542   Derivative/Non-derivative trans. at $87.97 per share. 135,649
12/10/2022 Andrew D. Dickinson
Chief Financial Officer 		480   Derivative/Non-derivative trans. at $87.97 per share. 42,225
12/10/2022 Johanna Mercier
Chief Commercial Officer 		463   Derivative/Non-derivative trans. at $87.97 per share. 40,730
12/10/2022 Merdad V. Parsey
Chief Medical Officer 		486   Derivative/Non-derivative trans. at $87.97 per share. 42,753
12/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		149   Derivative/Non-derivative trans. at $87.97 per share. 13,107
12/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		3,300   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Andrew D. Dickinson
Chief Financial Officer 		1,027   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Johanna Mercier
Chief Commercial Officer 		990   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Merdad V. Parsey
Chief Medical Officer 		1,039   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		318   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2022 Andrew D. Dickinson
Chief Financial Officer 		851   Derivative/Non-derivative trans. at $82.6 per share. 70,292
11/10/2022 Merdad V. Parsey
Chief Medical Officer 		2,268   Derivative/Non-derivative trans. at $82.6 per share. 187,336
11/10/2022 Andrew D. Dickinson
Chief Financial Officer 		1,912   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2022 Merdad V. Parsey
Chief Medical Officer 		5,099   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/gild

MarketWatch News on GILD

  1. Moderna Inc. stock falls Thursday, underperforms market

    4:32 p.m. Today

    - MarketWatch Automation

  2. Moderna Inc. stock rises Wednesday, still underperforms market

    4:31 p.m. March 29, 2023

    - MarketWatch Automation

  3. Moderna Inc. stock falls Tuesday, underperforms market

    4:31 p.m. March 28, 2023

    - MarketWatch Automation

  4. Moderna Inc. stock underperforms Monday when compared to competitors

    4:31 p.m. March 27, 2023

    - MarketWatch Automation

  6. Moderna Inc. stock rises Thursday, still underperforms market

    4:31 p.m. March 23, 2023

    - MarketWatch Automation

  7. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. March 22, 2023

    - MarketWatch Automation

  8. Moderna Inc. stock falls Tuesday, underperforms market

    4:31 p.m. March 21, 2023

    - MarketWatch Automation

  9. Moderna Inc. stock rises Monday, outperforms market

    4:31 p.m. March 20, 2023

    - MarketWatch Automation

  11. Nurix’s stock rallies on Gilead’s option

    9:00 a.m. March 20, 2023

    - Jaimy Lee

  12. Moderna Inc. stock underperforms Friday when compared to competitors

    4:31 p.m. March 17, 2023

    - MarketWatch Automation

  13. Moderna Inc. stock rises Thursday, still underperforms market

    4:31 p.m. March 16, 2023

    - MarketWatch Automation

  14. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. March 15, 2023

    - MarketWatch Automation

  15. Moderna Inc. stock rises Tuesday, outperforms market

    4:31 p.m. March 14, 2023

    - MarketWatch Automation

  16. Moderna Inc. stock rises Monday, outperforms market

    4:31 p.m. March 13, 2023

    - MarketWatch Automation

  17. Moderna Inc. stock rises Friday, outperforms market

    4:31 p.m. March 10, 2023

    - MarketWatch Automation

  18. Moderna Inc. stock falls Thursday, underperforms market

    4:31 p.m. March 9, 2023

    - MarketWatch Automation

  19. Moderna Inc. stock rises Wednesday, outperforms market

    4:31 p.m. March 8, 2023

    - MarketWatch Automation

  20. Moderna Inc. stock falls Tuesday, underperforms market

    4:31 p.m. March 7, 2023

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/gild

Other News on GILD

  1. Higher Rates Are Coming for U.S. Companies

    7:24 a.m. March 28, 2023

    - Justin Lahart

  4. First Drugs Facing Medicare Price Penalty Are Named

    12:50 p.m. March 15, 2023

    - Stephanie Armour

  5. Seagen’s Cancer Therapy Is Making It a Takeover Target

    12:29 p.m. March 6, 2023

    - Jared S. Hopkins

  6. Guild Esports launches Guild Studios

    5:00 a.m. March 2, 2023

    - TheNewswire.ca

  7. 10-K: GILEAD SCIENCES, INC.

    4:30 p.m. Feb. 22, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  9. AQR CAPITAL MANAGEMENT LLC Buys 3, Sells 2 in 4th Quarter

    10:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  10. VALUEWORKS LLC Buys 1, Sells 4 in 4th Quarter

    8:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  11. Top 5 4th Quarter Trades of HealthInvest Partners AB

    6:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  12. Top 5 4th Quarter Trades of Nan Shan Life Insurance Co., Ltd.

    2:00 p.m. Feb. 16, 2023

    - GuruFocus.com

  13. Top 5 4th Quarter Trades of Avalon Investment & Advisory

    2:00 a.m. Feb. 15, 2023

    - GuruFocus.com

  14. Caxton Associates Buys 4, Sells 1 in 4th Quarter

    6:00 p.m. Feb. 14, 2023

    - GuruFocus.com

  15. John Rogers Buys 3, Sells 2 in 4th Quarter

    10:00 a.m. Feb. 14, 2023

    - GuruFocus.com

  16. This Top Dividend Stock Just Hiked Its Payouts Again

    11:59 a.m. Feb. 13, 2023

    - Baystreet.ca

  17. GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter

    4:00 p.m. Feb. 12, 2023

    - GuruFocus.com

  18. Top 5 4th Quarter Trades of KLCM Advisors, Inc.

    4:00 p.m. Feb. 12, 2023

    - GuruFocus.com

  19. Goodman Financial CORP Buys 2, Sells 3 in 4th Quarter

    2:00 p.m. Feb. 9, 2023

    - GuruFocus.com

  20. Top 5 4th Quarter Trades of VAN ECK ASSOCIATES CORP

    2:00 p.m. Feb. 8, 2023

    - GuruFocus.com

  21. Loading more headlines...

At a Glance

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, California 94404

Phone

1 6505743000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$27.09B

Net Income

$4.59B

Employees

17,000

Annual Report for GILD

/news/pressrelease/company/us/gild

Press Releases on GILD

  3. How To Trade Gilead Sciences $GILD

    7:52 p.m. March 23, 2023

    - Stock Traders Daily

  4. PSQ, IBBQ: Big ETF Outflows

    10:50 a.m. March 23, 2023

    - MarketNewsVideo.com

  15. Gilead Sciences $GILD Investment Analysis and Advice

    4:17 a.m. March 14, 2023

    - Stock Traders Daily

  18. Gilead Sciences $GILD Technical Pivots with Risk Controls

    1:11 p.m. March 4, 2023

    - Stock Traders Daily

  20. Guild Esports launches Guild Studios

    6:00 a.m. March 2, 2023

    - TheNewswire.ca

  21. Loading more headlines...
Link to MarketWatch's Slice.